Related Experiment Video
Updated: Nov 12, 2025
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
Published on: May 24, 2024
A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα)
James M Kelly1, Thomas M Jeitner1, Shashikanth Ponnala1,2
1Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, NY, 10065, USA.
Purpose:
Fibroblast activation protein-α (FAPα) is uniquely expressed in activated fibroblasts, including cancer-associated fibroblasts that populate tumor stroma and contribute to proliferation and immunosuppression. Radiolabeled FAPα inhibitors enable imaging of multiple human cancers, but time-dependent clearance from tumors currently limits their utility as FAPα-targeted radiotherapeutics. We sought to increase the area under the curve (AUC) by constructing a trifunctional ligand that binds FAPα with high affinity and also binds albumin and theranostic radiometals.
Procedures:
RPS-309 comprised a FAPα-targeting moiety, an albumin-binding group, and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Inhibition of recombinant human FAPα (rhFAPα) was determined by colorimetric assay. Affinity for human serum albumin (HSA) was determined by high-performance affinity chromatography. The tissue distribution of [68Ga]Ga-RPS-309 in SW872 tumor xenograft-bearing mice was imaged by microPET/CT and quantified by biodistribution studies performed from 30 min to 3 h post injection (p.i.). The biodistribution of [177Lu]Lu-RPS-309 was determined at 4, 24, and 96 h p.i.
Results:
RPS-309 inhibits rhFAPα with IC50 = 7.3 ± 1.4 nM. [68Ga]Ga-RPS-309 is taken up specifically by FAPα-expressing cells and binds HSA with Kd = 4.6 ± 0.1 μM. Uptake of the radiolabeled ligand in tumors was evident from 30 min p.i. (> 5 %ID/g) and was significantly reduced by co-injection of RPS-309. Specific skeletal uptake was also observed. Activity in tumors was constant through 4 h p.i., but cleared significantly by 24 h. The AUC in this period was 127 (%ID/g) × h.
Conclusions:
RPS-309 is a high-affinity FAPα inhibitor with prolonged plasma residence. Introduction of the albumin-binding group did not compromise FAPα binding. Although initial tumor uptake was high and FAPα-specific, RPS-309 also progressively cleared from tumors. Nevertheless, RPS-309 incorporates multiple sites in which structural diversity can be introduced, and therefore serves as a platform for future structure-activity relationship studies.
Insights
A novel trifunctional ligand, RPS-309, targets fibroblast activation protein-alpha (FAPα) and albumin, showing potential for cancer imaging and therapy. While clearance from tumors limits radiotherapeutic use, RPS-309 serves as a platform for future drug development.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Imaging
Background:
- Fibroblast activation protein-alpha (FAPα) is a key marker in tumor stroma, implicated in cancer progression and immune suppression.
- Current FAPα-targeted radiopharmaceuticals face limitations due to rapid tumor clearance, hindering therapeutic efficacy.
- Developing agents with enhanced tumor retention is crucial for effective FAPα-targeted therapies.
Purpose of the Study:
- To design and evaluate a trifunctional ligand (RPS-309) for enhanced targeting of FAPα.
- To incorporate an albumin-binding moiety to prolong plasma residence time and potentially improve tumor exposure.
- To assess the theranostic potential of RPS-309 by evaluating its binding affinity, specificity, and biodistribution.
Main Methods:
- Synthesis of RPS-309, a ligand combining FAPα targeting, albumin binding, and a DOTA chelator for radiometals.
- In vitro assessment of FAPα inhibition and human serum albumin (HSA) binding affinity.
- In vivo microPET/CT imaging and biodistribution studies of radiolabeled [68Ga]Ga-RPS-309 and [177Lu]Lu-RPS-309 in tumor xenograft models.
Main Results:
- RPS-309 demonstrated high-affinity inhibition of FAPα (IC50 = 7.3 ± 1.4 nM) and specific binding to HSA (Kd = 4.6 ± 0.1 μM).
- Radiolabeled RPS-309 showed specific tumor uptake in FAPα-expressing xenografts, with activity remaining constant for up to 4 hours post-injection.
- Despite initial high uptake, significant tumor clearance was observed by 24 hours, limiting the area under the curve (AUC) to 127 (%ID/g) × h.
Conclusions:
- RPS-309 is a high-affinity FAPα inhibitor with an albumin-binding group that enhances plasma residence time without compromising FAPα binding.
- While FAPα-specific tumor uptake was observed, progressive clearance limits its current utility as a radiotherapeutic.
- RPS-309 provides a versatile platform for future structure-activity relationship studies to optimize FAPα-targeted agents.
More Related Videos
10:33Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Related Concept Videos
Introduction to Fibroblasts
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Intracellular Signaling Affects Focal Adhesions
Some...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
TGF - β Signaling Pathway
Fibronectins Connect Cells with ECM
Both proteoglycans and collagen are attached to fibronectin proteins, which, in turn, are attached to integrin proteins. These integrin proteins interact with transmembrane...